Live Live update #3

Analysts’ Top 5 Questions for UiPath Ahead of Tonight’s Q2 Earnings

With UiPath (NYSE:PATH | PATH Price Prediction) reporting after the close, here is what to listen for on the 5:00 PM ET call.

Top 5 Analyst Questions

  1. Is net new ARR reaccelerating above the $49 million posted in Q1?
  2. How much is agentic AI contributing, given 16 of the top 20 deals already include it?
  3. Path to the 30% long-term non-GAAP margin target?
  4. Competitive wins versus Microsoft Power Automate and Salesforce Agentforce?
  5. Pace of buybacks after $243.8M repurchased in Q1?

Key Topics and Buzzwords

  • Maestro Case, UiPath for Coding Agents, WorkFusion contribution, outcome-based pricing.
  • Listen for “orchestration,” “deterministic plus agentic,” “pilot to production.”

Red Flags

  • ARR at the low end of $1.929B-$1.934B.
  • DBNR slipping below 109%.
  • Any full-year guide trim versus the $1.776B-$1.781B range, which would jeopardize the 37.85% one-month rally.

Contact [email protected] for any questions or corrections.

More From This Coverage

Newest first
Thomas Richmond

That wraps up our initial coverage of UiPath’s Q2 results. Thank you for stopping by!

Thomas Richmond

UiPath just reported earnings, with shares initially up 12% following the report. Here are the key numbers:

  • Revenue: $410.26M vs. $397.85M expected
  • Adjusted EPS: $0.15 vs. $0.15 expected

Quick Read:

UiPath beat revenue expectations by roughly 3% while adjusted EPS came in exactly in line with Wall Street estimates.

The 12% initial surge suggests investors like the top-line momentum, with revenue growing 13% year over year as Wall Street looks for evidence that UiPath’s agentic AI strategy is accelerating growth.

Thomas Richmond

Bull Case: Momentum, Margins, and Agentic Traction

  • Consistent revenue beats: Q2 FY26 by 4.14%, Q3 FY26 by 4.64%, Q4 FY26 by 3.51%, Q1 FY27 by 5.26%, with Q1 revenue of $418 million, up 17%.
  • 16 of the top 20 deals included AI, and AI expansion deals ran six times larger.
  • GAAP profitability arrived for the first time, with Q1 non-GAAP operating margin at 22%.
  • EPS revisions skew positive: 10 upward vs. 5 downward in 30 days.

Bear Case: High Bar, Decelerating Growth

  • Shares are up 37.85% in one month, raising the setup risk.
  • ARR growth is stuck near 11%-12%, well below prior levels.
  • Q1 EPS missed by 5.48%, and analysts remain 16 Hold vs. 3 Buy.
  • Insider direction is selling, an odd counterpoint to the rally.
Thomas Richmond

Insider Activity Scorecard

Date Insider Title Transaction Shares Price
2026-08-19 Daniel Dines CEO & Chairman Sell 1,402,347 $16.07
2026-08-14 Hitesh Ramani Chief Accounting Officer Sell 25,000 $16.75
2026-08-13 Hitesh Ramani Chief Accounting Officer Sell 25,000 $16.50
2026-07-01 Ashim Gupta COO & CFO Sell 30,526 $10.87
2026-07-01 Raghavendra Malpani CPO & CTO Sell 25,837 $10.87

Insider activity at UiPath (NYSE:PATH) over the past 90 days skewed decisively toward selling.

  • CEO Daniel Dines’ August 19 disposal of over 1.4 million shares dwarfed every other filing.
  • Chief Accounting Officer Hitesh Ramani added back-to-back sales in the mid-$16s.
  • July 1 dispositions from Gupta, Malpani, and Legal Chief Brad Brubaker at $10.87 appear tied to vesting.

The only acquisitions were six identical 19,175-share director grants on June 25 at $0.00, reflecting equity awards rather than open-market conviction. Dashboard data confirms net insider direction is selling.

With shares up 37.85% in a month, executives leaned into strength rather than adding exposure ahead of tonight’s earnings report, a caution flag against the setup.

Thomas Richmond

UiPath is expected to report fiscal Q2 2027 earnings at 4:10 PM ET, with Wall Street looking for evidence that its agentic AI push is translating into stronger recurring revenue growth.

Management has guided for revenue of $395-$400 million and ARR between roughly $1.929-$1.934 billion. Investors will also be watching net new ARR, with a figure above roughly $49 million providing another signal that growth is accelerating.

The stakes are high after UiPath shares soared around 40% over the past month. A higher full-year ARR outlook could validate the rally and strengthen the case that UiPath is evolving from a traditional automation vendor into a broader enterprise AI orchestration platform.

A guidance cut would tell a very different story and could put much of the stock’s recent rally at risk.

View the full live blog (6 updates) →